Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) @NEJMgroup
Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) @NEJMgroup
Uploaded April 2026 | Updated September 2026, 1 week ago
In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Read the full trial results and Research Summary at NEJM.org.

#neurology #hematology #nejm
Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE)Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (LITESPARK-022)NEJM Interview: Sara Gerke on a Utah pilot program involving an AI system that autonomously renew...NEJM Interview: Yaara Zisman-Ilani on navigating the uncertainty surrounding medication managemen...Ask the Expert: HFpEF Standard of CareMoney and MisdiagnosisNEJM This Week — June 25, 2026Images in Clinical Medicine: Cerebral Syphilitic GummaClinical Practice: SyncopeNEJM Clinician: The Troubling Rise of Medical Credit CardsJoseph Graves, PhD, on the Myth of Race and GeneticsSubacute Sclerosing Panencephalitis
NEJM Group |

Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER